This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Virpax Pharmaceuticals’s 8K filing here.
About Virpax Pharmaceuticals
Virpax Pharmaceuticals, Inc, a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain.
Further Reading
- Five stocks we like better than Virpax Pharmaceuticals
- What to Know About Investing in Penny Stocks
- Price Plunge in Roblox Presents Opportunity for Robust Gains
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- Billions in Buybacks: 4 Stocks Rewarding Shareholders Now
- How to Calculate Stock Profit
- 3 Steel Stocks to Gain Strength as Tariffs Reshape the Market
